Wall Street Zen Upgrades Pulmonx (NASDAQ:LUNG) to “Hold”

Pulmonx (NASDAQ:LUNG) was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued on Saturday.

Several other research firms have also recently issued reports on LUNG. Canaccord Genuity Group decreased their target price on shares of Pulmonx from $6.00 to $5.00 and set a “buy” rating for the company in a research note on Thursday, March 5th. D. Boral Capital reaffirmed a “buy” rating and issued a $14.00 price objective on shares of Pulmonx in a report on Thursday, April 30th. Four investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $5.58.

Pulmonx Stock Performance

Shares of LUNG opened at $1.25 on Friday. The stock has a 50-day moving average of $1.39 and a two-hundred day moving average of $1.63. The stock has a market cap of $52.80 million, a P/E ratio of -0.96 and a beta of 0.28. Pulmonx has a one year low of $1.13 and a one year high of $3.88. The company has a debt-to-equity ratio of 0.81, a quick ratio of 4.04 and a current ratio of 4.91.

Pulmonx (NASDAQ:LUNG) last posted its quarterly earnings results on Wednesday, April 29th. The company reported ($0.33) EPS for the quarter, meeting the consensus estimate of ($0.33). Pulmonx had a negative net margin of 60.09% and a negative return on equity of 92.94%. The company had revenue of $20.59 million for the quarter, compared to analyst estimates of $20.43 million. As a group, research analysts predict that Pulmonx will post -1.13 EPS for the current year.

Institutional Investors Weigh In On Pulmonx

A number of institutional investors have recently added to or reduced their stakes in LUNG. Cerity Partners LLC purchased a new stake in Pulmonx in the 4th quarter worth $27,000. Opal Capital LLC acquired a new stake in shares of Pulmonx in the fourth quarter valued at about $29,000. Regatta Capital Group LLC acquired a new stake in shares of Pulmonx in the fourth quarter valued at about $30,000. Lazard Asset Management LLC purchased a new stake in shares of Pulmonx during the fourth quarter worth about $31,000. Finally, FNY Investment Advisers LLC purchased a new stake in shares of Pulmonx during the third quarter worth about $29,000. Institutional investors and hedge funds own 91.04% of the company’s stock.

Pulmonx Company Profile

Pulmonx Corporation is a commercial-stage medical device company focused on bronchoscopic lung volume reduction for patients suffering from severe emphysema. The company’s flagship therapy, the Zephyr® Endobronchial Valve System, employs one-way valves delivered via a minimally invasive bronchoscopic procedure to collapse diseased portions of the lung, reducing hyperinflation and improving respiratory function. Complementing this treatment, Pulmonx offers the Chartis® Pulmonary Assessment System, which provides clinicians with quantitative measurements of collateral ventilation to aid in patient selection and optimize clinical outcomes.

The Zephyr Valve received the CE mark in Europe in 2008 and FDA approval in the United States in 2018, and it has since been adopted by leading respiratory and thoracic centers across North America and Europe.